

8116104

1FW



Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h2 style="margin: 0;">TRANSMITTAL FORM</h2> <p style="margin: 5px 0;">(to be used for all correspondence after initial filing)</p>		Application Number	10/719,006
		Filing Date	November 20, 2003
		First Named Inventor	HORI, NOBUAKI
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	4	Attorney Docket Number	ABJT-004CON5
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08a Form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <p style="margin: 5px 0;">Postcard</p>	
<div style="display: flex; justify-content: space-between;"> Remarks </div>			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36.513 BOZIOVIC, FIELD & FRANCIS LLP		
Signature			
Date	August 13, 2004		
EXPRESS MAIL LABEL NO. EV 462737715 US			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



EXPRESS MAIL LABEL NO. EV 462737715 US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	ABJT-004CON5
	First Named Inventor	HORI, NOBUAKI
	Application Number	10/719,006
	Confirmation No.	9100
	Filing Date	November 20, 2003
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
	Title:	"PRODUCTION OF A MULTIMERIC PROTEIN BY CELL FUSION METHOD"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent applications Serial No. 09/945,387 (now U.S. Patent No. 6,677,138), Serial No. 09/769,070 (now U.S. Patent No. 6,420,140), Serial No. 09/342,301 (Now U.S. Patent No. 6,207,418) and Serial No. 08/730,639 (now U.S. Patent No. 5,916,771) as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. ABJT-004CON5 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Aug 13, 2004

By: Carol L. Francis
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/719,006	
			Filing Date	November 20, 2003	
			First Named Inventor	HORI, NOBUAKI	
			Art Unit	1645	
Sheet	1	of	2	Examiner Name	
				Attorney Docket Number	ABJT-004CON5

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		4.816.397		Boss et al.	3/28/1989	
		4.816.567		Cabilly Ct al.	3/28/1989	
		4.975.369		Beavers et al.	12/4/1990	
		5.202.238		Fell et al.	4/13/1993	
		5.643.745		Stuart	7/1/1997	
		5.683.899		Stuart	11/4/1997	
		5.695.965		Stuart et al.	12/9/1997	
		5.916.771		Hori et al.	06/29/1999	
		6.207.418		Hori et al.	03/27/2001	
		6.420.140		Hori et al.	07/16/2002	
		6.677.138		Hori et al.	01/13/2004	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		273 889	7/1988			
		0 088 994 Bi	6/1991			
		WO 86/01533	3/1986			
		WO 92/15322	9/1992			
		WO 93/19172	9/1993			
		WO 93/25663	12/1993			
		WO 94/02602	2/1994			
		WO 95/02686	1/1995			
		WO 95/30739	11/1995			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/719,006		
		Filing Date	November 20, 2003		
		First Named Inventor	HORI, NOBUAKI		
		Group Art Unit	1645		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	ABJT-004CON5

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wood, et al., "High Level Synthesis of Immunoglobulins in Chinese Hamster Ovary Cells," J.Immunol. 145(9):3011-3016 (Nov. 1, 1990).	
		Bebbington, C.R., (1991) "Expression of Antibody Genes in Nonlymphoid Mammalian Cells," Methods: A Companion to Methods Enzymol. 2:136-145.	
		Bebbington, C.R., et al., (1992) "High-level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene As An Amplifiable Selectable Marker," Bio/Technology 10:169-175	
		Caron, P.C., et al., (1992) "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," J. Exp. Med. 176:1191-1195.	
		Cattaneo, A. and Neuberger, M.S., (1987) "Polymeric Immunoglobulin M Is Secreted by Transfectants of Non- lymphoid Cells in the Absence of Immunoglobulin J Chain," EMBO J. 6:2753-2758.	
		Cockett, M.I., et al., (1990) "High-level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification," Bio/Technology 8:662-667.	
		Graham, FL., and Vander Eb, A.J., (1973) "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," Virology 52:456-67.	
		Riechmann, L. et al., (1988) "Reshaping Human Antibodies for Therapy," Nature 332:323-327.	
		Kranenborg, et al., "Development and Characterization of Anti-Renal Cell Carcinoma XAntichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," Cancer Research (Dec.1995), vol.55, No.23, pp. 5864S-5867S.	
		Cao, et al., "A Rapid Non-Selective Method to Generate Quadromas by Microelectrofusion," J. JYnmunol. Methods (Nov.16, 1995), vol.187, No.1, pp.1-7	
		Salazar-Kish, et al., "Comparison of a Quadroma and its Parent Hybridomas in Fed Batch Culture," A Biotechniogy (1993), vol.30, No.3, pp.351-365.	
		Bos, et al., "Enhanced Transfusion of a Bacterial Plasmid of Hybrid Hybridoma (Quadroma Cell) Lines," Hybridoma (Feb.1992), vol.11, No.1, pp.41-51.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.